Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abrocitinib expanded access for moderate to severe atopic dermatitis
NL-OMON52169Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of abrocitinib in atopic dermatitis (AD) (2 arms), sponsored by Pfizer. Started Oct 2021; status: active, not recruiting.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON52169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52169.